These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 37414222)

  • 21. Advances in aptamers against Aβ and applications in Aβ detection and regulation for Alzheimer's disease.
    Zheng Y; Zhang L; Zhao J; Li L; Wang M; Gao P; Wang Q; Zhang X; Wang W
    Theranostics; 2022; 12(5):2095-2114. PubMed ID: 35265201
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nanotechnology solutions for Alzheimer's disease: advances in research tools, diagnostic methods and therapeutic agents.
    Nazem A; Mansoori GA
    J Alzheimers Dis; 2008 Mar; 13(2):199-223. PubMed ID: 18376062
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exploring the Potential of Therapeutic Agents Targeted towards Mitigating the Events Associated with Amyloid-β Cascade in Alzheimer's Disease.
    Behl T; Kaur I; Fratila O; Brata R; Bungau S
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33050199
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasmonic Nanoparticles as Optical Sensing Probes for the Detection of Alzheimer's Disease.
    Oyarzún MP; Tapia-Arellano A; Cabrera P; Jara-Guajardo P; Kogan MJ
    Sensors (Basel); 2021 Mar; 21(6):. PubMed ID: 33809416
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The interactions of p53 with tau and Aß as potential therapeutic targets for Alzheimer's disease.
    Jazvinšćak Jembrek M; Slade N; Hof PR; Šimić G
    Prog Neurobiol; 2018 Sep; 168():104-127. PubMed ID: 29733887
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Untangling amyloid-β, tau, and metals in Alzheimer's disease.
    Savelieff MG; Lee S; Liu Y; Lim MH
    ACS Chem Biol; 2013 May; 8(5):856-65. PubMed ID: 23506614
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.
    Xin SH; Tan L; Cao X; Yu JT; Tan L
    Neurotox Res; 2018 Oct; 34(3):733-748. PubMed ID: 29626319
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathological Impacts of Chronic Hypoxia on Alzheimer's Disease.
    Zhang F; Niu L; Li S; Le W
    ACS Chem Neurosci; 2019 Feb; 10(2):902-909. PubMed ID: 30412668
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting Abeta and tau in Alzheimer's disease, an early interim report.
    Golde TE; Petrucelli L; Lewis J
    Exp Neurol; 2010 Jun; 223(2):252-66. PubMed ID: 19716367
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Subthreshold Amyloid Predicts Tau Deposition in Aging.
    Leal SL; Lockhart SN; Maass A; Bell RK; Jagust WJ
    J Neurosci; 2018 May; 38(19):4482-4489. PubMed ID: 29686045
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Search for Alzheimer's disease biomarkers in blood cells: hypotheses-driven approach.
    Wojsiat J; Laskowska-Kaszub K; Mietelska-Porowska A; Wojda U
    Biomark Med; 2017 Oct; 11(10):917-931. PubMed ID: 28976776
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multifunctional Selenium Quantum Dots for the Treatment of Alzheimer's Disease by Reducing Aβ-Neurotoxicity and Oxidative Stress and Alleviate Neuroinflammation.
    Guo X; Lie Q; Liu Y; Jia Z; Gong Y; Yuan X; Liu J
    ACS Appl Mater Interfaces; 2021 Jul; 13(26):30261-30273. PubMed ID: 34169710
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amyloid Beta and Phosphorylated Tau-Induced Defective Autophagy and Mitophagy in Alzheimer's Disease.
    Reddy PH; Oliver DM
    Cells; 2019 May; 8(5):. PubMed ID: 31121890
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in Alzheimer's Diagnosis and Therapy: The Implications of Nanotechnology.
    Hajipour MJ; Santoso MR; Rezaee F; Aghaverdi H; Mahmoudi M; Perry G
    Trends Biotechnol; 2017 Oct; 35(10):937-953. PubMed ID: 28666544
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Nanoplasmonic Biosensor for Ultrasensitive Detection of Alzheimer's Disease Biomarker Using a Chaotropic Agent.
    Kim H; Lee JU; Kim S; Song S; Sim SJ
    ACS Sens; 2019 Mar; 4(3):595-602. PubMed ID: 30747516
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Versatile and efficient targeting using a single nanoparticulate platform: application to cancer and Alzheimer's disease.
    Le Droumaguet B; Nicolas J; Brambilla D; Mura S; Maksimenko A; De Kimpe L; Salvati E; Zona C; Airoldi C; Canovi M; Gobbi M; Magali N; La Ferla B; Nicotra F; Scheper W; Flores O; Masserini M; Andrieux K; Couvreur P
    ACS Nano; 2012 Jul; 6(7):5866-79. PubMed ID: 22725248
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amyloid-β as a biomarker for Alzheimer's disease: quantification methods in body fluids.
    Galozzi S; Marcus K; Barkovits K
    Expert Rev Proteomics; 2015 Aug; 12(4):343-54. PubMed ID: 26153725
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alzheimer's disease: many failed trials, so where do we go from here?
    Reiss AB; Glass AD; Wisniewski T; Wolozin B; Gomolin IH; Pinkhasov A; De Leon J; Stecker MM
    J Investig Med; 2020 Aug; 68(6):1135-1140. PubMed ID: 32699179
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reducing Aβ load and tau phosphorylation: Emerging perspective for treating Alzheimer's disease.
    Kalra J; Khan A
    Eur J Pharmacol; 2015 Oct; 764():571-581. PubMed ID: 26209363
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of mitochondrial dysfunction, oxidative stress and autophagy in progression of Alzheimer's disease.
    Bhatia V; Sharma S
    J Neurol Sci; 2021 Feb; 421():117253. PubMed ID: 33476985
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.